Literature DB >> 10502725

Alteration of pRb/p16/cdk4 regulation in human osteosarcoma.

M S Benassi1, L Molendini, G Gamberi, P Ragazzini, M R Sollazzo, M Merli, J Asp, G Magagnoli, A Balladelli, F Bertoni, P Picci.   

Abstract

Cell-cycle regulation depends on a fine balance between cyclin-cyclin-dependent kinase complexes and a family of kinase inhibitors that bind cyclin-cdk complexes and block their activity. To investigate the role of mechanisms regulating cell-cycle progression in human osteosarcomas (OS), pRb/p16/cdk4 expression was analyzed in 39 high-grade OS; 19 of these developed metastasis during follow-up. Positive reaction for functional pRB was shown by 18/39 (46%) OS, while 21/39 (54%) were negative. A higher probability of metastasis was seen in patients with negative pRb expression (p < 0.05). Furthermore, while functional pRb and D1 expression are inversely associated to metastasis occurrence, the presence of D1/cdk4 complex in our study was related to poor prognosis. We found that 10/18 pRb-positive and 14/21 pRb-negative tumors were p16-positive. No significant correlation was found between pRb and p16 expression. On the other hand, high cdk4 levels in p16-positive tumors as compared with p16-negative tumors resulted in a positive association between p16 and cdk4 expression (Chi squared = 5.98; p = 0.01). No extensive p16INK4A genomic alterations were found in tumors lacking p16-protein expression. To determine which mechanisms are involved in the down-regulation of p16 protein, the methylation status of the p16INK4 gene was evaluated on the 15 p16-negative tumors: 8 samples showed 5' CpG-island methylation; 4/8 had a complete methylation status, while in the remaining 4 the gene was only partially methylated. These data confirm the role of the pRb/p16/cdk4 pathway in OS development. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10502725     DOI: 10.1002/(sici)1097-0215(19991022)84:5<489::aid-ijc7>3.0.co;2-d

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  30 in total

1.  CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest.

Authors:  Ashleigh M Francis; Angela Alexander; Yanna Liu; Smruthi Vijayaraghavan; Kwang Hui Low; Dong Yang; Tuyen Bui; Neeta Somaiah; Vinod Ravi; Khandan Keyomarsi; Kelly K Hunt
Journal:  Mol Cancer Ther       Date:  2017-06-15       Impact factor: 6.261

2.  Molecular basis of differentiation therapy for soft tissue sarcomas.

Authors:  Gaurav Luther; Richard Rames; Eric R Wagner; Gaohui Zhu; Qing Luo; Yang Bi; Stephanie H Kim; Jian-Li Gao; Enyi Huang; Ke Yang; Linyuan Wang; Xing Liu; Mi Li; Ning Hu; Yuxi Su; Xiaoji Luo; Liang Chen; Jinyong Luo; Rex C Haydon; Hue H Luu; Lan Zhou; Tong-Chuan He
Journal:  Trends Cancer Res       Date:  2010

Review 3.  Osteosarcoma development and stem cell differentiation.

Authors:  Ni Tang; Wen-Xin Song; Jinyong Luo; Rex C Haydon; Tong-Chuan He
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

Review 4.  A review of clinical and molecular prognostic factors in osteosarcoma.

Authors:  Jonathan C M Clark; Crispin R Dass; Peter F M Choong
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-27       Impact factor: 4.553

5.  Chick embryo extract demethylates tumor suppressor genes in osteosarcoma cells.

Authors:  Xiaodong Mu; Bolat Sultankulov; Riddhima Agarwal; Adel Mahjoub; Trevor Schott; Nicholas Greco; Johnny Huard; Kurt Weiss
Journal:  Clin Orthop Relat Res       Date:  2014-03       Impact factor: 4.176

Review 6.  Therapy for osteosarcoma: where do we go from here?

Authors:  Alexander J Chou; David S Geller; Richard Gorlick
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 7.  Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies.

Authors:  James J Morrow; Chand Khanna
Journal:  Crit Rev Oncog       Date:  2015

8.  The Current and Future Therapies for Human Osteosarcoma.

Authors:  Joseph D Lamplot; Sahitya Denduluri; Jiaqiang Qin; Ruidong Li; Xing Liu; Hongyu Zhang; Xiang Chen; Ning Wang; Abdullah Pratt; Wei Shui; Xiaoji Luo; Guoxin Nan; Zhong-Liang Deng; Jinyong Luo; Rex C Haydon; Tong-Chuan He; Hue H Luu
Journal:  Curr Cancer Ther Rev       Date:  2013-02

9.  Genetically engineered mouse models and human osteosarcoma.

Authors:  Alvin Jm Ng; Anthony J Mutsaers; Emma K Baker; Carl R Walkley
Journal:  Clin Sarcoma Res       Date:  2012-10-04

10.  A new approach for prediction of tumor sensitivity to targeted drugs based on functional data.

Authors:  Noah Berlow; Lara E Davis; Emma L Cantor; Bernard Séguin; Charles Keller; Ranadip Pal
Journal:  BMC Bioinformatics       Date:  2013-07-29       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.